Why Merck Stock Jumped 70%?
Between June 2025 and February 2026, Merck (MRK) surged 67%, fueled more by investor excitement than just modest revenue and profit gains. Strong oncology sales, pipeline breakthroughs, and smart acquisitions sparked optimism—until cautious 2026 guidance triggered a notable pullback, tempering the rally’s pace.
Below is an analytical breakdown of stock movement into key contributing metrics.
| 6022025 | 2272026 | Change | |
|---|---|---|---|
| Stock Price ($) | 74.1 | 123.8 | 67.0% |
| Total Revenues ($ Mil) | 63,922.0 | 65,011.0 | 1.7% |
| Net Income Margin (%) | 27.3% | 28.1% | 2.9% |
| P/E Multiple | 10.7 | 16.8 | 56.9% |
| Shares Outstanding (Mil) | 2,523.0 | 2,481.0 | 1.7% |
| Cumulative Contribution | 67.0% |
So what is happening here? The stock jumped 67%, driven by a modest 1.7% revenue rise and a 2.9% profit margin boost, while a sharp 57% P/E multiple increase amplified investor enthusiasm.
Here Is Why Merck Stock Moved
- Oncology Segment Strength: Q3 2025 Keytruda sales rose 8% to $8.1B, demonstrating continued market penetration in metastatic and earlier-stage cancer indications.
- Animal Health Growth: The Animal Health segment’s revenue grew 9% in Q3 2025, driven by strong demand for livestock products and new companion animal product launches.
- Pipeline Execution: Announced positive results from 18 Phase 3 trials in 2025, showcasing progress in diversifying the pipeline beyond Keytruda.
- Proactive M&A: Completed the acquisition of Verona Pharma in Q3 2025, adding a new commercial product and bolstering the respiratory pipeline.
- Guarded 2026 Outlook: Disappointing 2026 EPS guidance of $5.00-$5.15, heavily impacted by a ~$3.95 per share charge from the Cidara Therapeutics acquisition, signals a near-term earnings reset.
Current Assesment Of MRK Stock
The core investment debate is centered around: Can Merck’s new product launches and pipeline (Winrevair, Capvaxive, subcutaneous Keytruda) generate enough revenue to offset the catastrophic 2028 loss of exclusivity for Keytruda, which represents nearly 50% of sales?
The prevailing sentiment appears to be neutral. Keytruda remains a rock, and the new launches are real. But the Gardasil franchise is cracking, and forward estimates are dropping due to M&A costs. The massive, unavoidable 2028 patent cliff keeps conviction in check.
| Bull View | Bear View |
|---|---|
| Strong initial sales from Winrevair and Capvaxive, plus the Keytruda life-cycle extension, provide a credible, tangible bridge to a future of diversified, durable growth post-2028. | The scale of the Keytruda revenue cliff is too large to overcome. Pipeline execution risk is high, as shown by recent failed M&A, and new products will face their own competitive pressures. |
Navigating the competing bull and bear cases of any single stock carries inherent volatility. Managing that idiosyncratic risk requires a broader portfolio framework.
Smart Investing Begins With Portfolios
Individual stocks are unpredictable. A smart portfolio helps you invest, limits downside shocks, and provides upside exposure.
The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 – the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? HQ Portfolio has posted more than 105% in cumulative return since inception, with less risk versus the benchmark index, as evident in HQ Portfolio performance metrics.